A major limitation in cancer gene therapy, specifically genedependent enzyme prodrug therapy (GDEPT), is inefficient gene delivery and expression. The suicide gene cytosine deaminase (CD) and its substrate, 5-fluorocytosine (5-FC), have been extensively explored due to the inherent 'bystander' effect achieved through diffusion of the toxic metabolite 5-fluorouracil (5-FU). In this study, we aimed to enhance this 'bystander' effect by fusing the Saccharomyces cerevisiae CD to the HSV-1 tegument protein vp22, a novel translocating protein. Two constructs were created: one with vp22 fused to CD (vp22CD) and a second wherein a truncated vp22, lacking the necessary residues for trafficking, fused to CD (delvp22CD). The generated 9L stable lines exhibited similar growth rates, enzyme expression, CD activity, and sensitivity to 5-FC and 5-FU. However, mixed population colony formation assays demonstrated greater bystander effect with the vp22CD fusion as compared to delvp22CD. This enhancement was maintained in vivo where 9L tumors expressing 20 or 50% vp22CD exhibited increased growth delay compared to the respective delvp22CD tumors. Moreover, adenoviral transduction of established wild-type 9L tumors showed increased growth delay with vp22CD (Ad-EF_vp22CD) as compared to equivalent CD (Ad-EF_CD) transduced tumors. Finally, confirming the increased efficacy, 19 F magnetic resonance spectroscopy (MRS) of vp22CD-expressing tumors demonstrated increased 5-FU levels as compared to tumors expressing the nontranslocating CD. These results together demonstrated that fusion of vp22 to CD resulted in CD translocation, which in turn amplified conversion of 5-FC to 5-FU in vivo and enhanced the therapeutic benefit of this GDEPT strategy.
Introduction
Gene-dependent enzyme prodrug therapy (GDEPT) has been proposed as a means to provide tumor-specific delivery of high concentrations of cytotoxic agents in the treatment of malignant neoplasms. 1 This strategy relies on the conversion of a nontoxic prodrug into a toxic metabolite by means of a nonmammalian enzyme. One such system that has been widely studied for GDEPT utilizes the nonmammalian enzyme cytosine deaminase (CD), which catalyzes the conversion of prodrug, 5-fluorocytosine (5-FC), into the toxic chemotherapeutic, 5-fluorouracil (5-FU). Though many other enzyme/ prodrug combinations have been explored, a particular advantage of the CD/5-FC system is the diffusibility of both the prodrug (5-FC) and the toxic metabolite (5-FU), leading to a greater bystander effect 2, 3 as compared to the Herpes simplex virus thymidine kinase (HSV-TK) and ganciclovir (GCV) system, where spread of the toxic metabolite only occurs through the gap junctions. 4 Recent attention to the CD/5-FC system has yielded many advances such as elucidation of a more catalytically active CD from Saccharomyces cerevisiae, leading to greater conversion of 5-FC to 5-FU and thereby offering a substantial benefit in tumor control. 5, 6 Additionally, concomitant expression or fusion of CD and uracil phosphoribosyltransferase increased conversion of 5-FC to 5-FU above wild-type yeast CD alone, and also led to increased production of 5-FUMP for greater cytotoxicity. [7] [8] [9] [10] [11] Although there have been major advances in improving the potency of this CD/5-FC system, several deficiencies inherent to all gene therapy strategies have led to limited therapeutic response. This common limitation of gene therapy strategies is attributed to the lack of efficient gene delivery and expression. [12] [13] [14] [15] [16] Studies have shown that using the CD GDEPT strategy even with low transduction levels down to 5% of tumor cells can lead to significant tumor regression. 17 Although these results are promising, rarely does this suicide gene therapy strategy lead to complete elimination of the tumors, and in most cases leads to re-growth once the treatment protocol is discontinued. Though advances have led to CD-based systems with improved catalytic efficiency for 5-FC to 5-FU conversion, there still lacks a resolution to address inefficient gene transfer and expression, which could provide further therapeutic benefit.
Recently, a class of proteins known as cell-penetrating peptides has garnered attention for exhibiting the unusual property of being able to transport into and out of cells via nonclassical mechanisms. [18] [19] [20] [21] The prototypical peptide in this novel family of proteins is the HSV-1 tegument protein, vp22, which has been extensively studied for its translocation properties, which indicated that vp22 can export from the cytoplasm of the expressing cell and import into a neighboring cell, where it accumulates in the nucleus. 22, 23 Moreover, studies have also shown that fusing vp22 to other proteins such as: GFP, [24] [25] [26] [27] [28] p53, 29 HSV-TK, 30, 31 or Escherichia coli CD, 32 neither ablates the translocation property of vp22 nor inhibits the function of the target protein.
Preclinical evaluation using the TK-vp22 fusion revealed an enhanced cytotoxicity in vitro and in vivo using mixed populations of wild-type and expressing cells. 33, 34 However, the inherent poor bystander effect of the HSV-TK/ GCV system likely limited the eventual efficacy of this system even with the assistance of vp22-mediated protein translocation. 30, 31 Similarly, the bacterial CDvp22 fusion resulted in an enhanced bystander effect in culture, although this system was not evaluated in an in vivo model. 32 In the studies reported here, a chimeric fusion between vp22 and S. cerivisiae CD (vp22CD) was generated to study the translocation properties of this fusion protein and also to determine whether there is a therapeutic benefit of using this molecule in a GDEPT strategy as opposed to the wild-type CD. Initial studies demonstrated in vitro that the translocatable CD fusion (vp22CD) had an enhanced bystander effect compared to a fusion between CD and vp22 that lacked the translocation domain. In vivo studies of 9L gliomas in nude mice either using stable cell lines or following transduction with an adenovirus coding for vp22CD or CD showed distinct differences between the translocatable and nontranslocatable forms of CD, where in both cases vp22CD resulted in an increase in specific growth delay following treatment with 5-FC. Moreover, immunostaining with anti-CD antibodies of 9L tumor sections, from 20% expressing tumors (vp22CD and delvp22CD), revealed transit of vp22CD to a nuclear location in neighboring cells, but this nuclear localization was not identified in cells expressing delvp22CD. Also, it has been previously reported that 19 F magnetic resonance spectroscopy (MRS) could provide in vivo quantification of the catalytic conversion of 5-FC to 5-FU due to differing spectral shifts of the fluorine signal. 35, 36 Using a similar 19 F MRS technique, in vivo studies demonstrated that tumors transduced with vp22CD resulted in increased intratumoral levels of 5-FU compared to tumors transduced with either CD or LacZ, which correlated with the enhancement in growth delay. In conclusion, these results further advocate that fusion of vp22 to yeast CD increases the functional distribution of the protein and further leads to enhanced therapeutic outcome following treatment with systemic 5-FC.
Results
The vp22CD fusion protein retains cytosine deaminase activity and translocates to nonexpressing cells
In order to study the ability of the vp22 protein to increase the bystander effect in the CD/5-FC GDEPT strategy, an expression plasmid coding for an aminoterminal fusion between the HSV-1 tegument protein vp22 and S. cerevisiae CD was constructed by a direct fusion in frame of the coding sequence of vp22 and CD (vp22CD). As a control, a CD fusion protein of a nonfunctional vp22, which lacked 34 C-terminal residues necessary for protein translocation, was also generated (delvp22CD) (Figure 1a) . 22 Both fusions were subcloned into the eukaryotic expression plasmid pEF, and stable cell lines expressing vp22CD and delvp22CD were generated in 9L gliosarcoma cells. Western blots performed on both 9Lvp22CD and 9Ldelvp22CD demonstrated a band at 55.5 kDa corresponding to vp22CD and a slightly smaller band (B51 kDa) corresponding to delvp22CD (Figure 1b) .
In order to compare the efficacy of vp22CD and delvp22CD, stable clones were selected, which exhibited similar CD expression based on Western analysis ( Figure  1b ) and CD activity (Figure 1c) . Growth inhibition assays also demonstrated that 100% expressing populations of vp22CD-expressing or delvp22CD-expressing cells had similar sensitivity to 5-FU as parental 9L cells (IC 50 B1 mM) ( Figure 1d ). As expected, wild-type 9L cells were resistant to 5-FC even up to 10 mM. However, stable cell lines expressing vp22CD or delvp22CD both exhibited greater than 10 000-fold sensitization to 5-FC with an IC 50 of 2-3 mM, which approached their baseline sensitivity to 5-FU (Figure 1d ). This was similar to previous reports for cell lines expressing yeast CD alone, which suggests that the fusion protein had no significant impact upon CD activity. 37 
Cytotoxic effect of 5-FC on bystander cells
The CD/5-FC GDEPT strategy has been reported to have a greater bystander effect as compared to other gene therapy strategies such as HSVtk/GCV; however, with tumors comprised of a small fraction of CD-expressing cells, there was still a limited growth delay. 38 In theory, by allowing translocation of the CD enzyme to nontransduced cells, the vp22CD fusion might potentiate this bystander effect. In order to investigate if the ability of vp22 to mediate cell-to-cell trafficking of CD resulted in enhanced bystander killing, 9L stable cell lines were used in coculture experiments and clonogenic assays were performed following 5-FC treatment to determine their surviving fraction. Cocultures consisting of 0, 5, 10, 20 or 50% vp22CD or delvp22CD (with wild-type 9L cells making up the remainder of each culture) were established, and then treated with 100 mM 5-FC for either 12 or 24 h prior to plating to assess colony formation ( Figure  2 ). Similar to the results observed above (Figure 1d ), in the absence of vp22CD-or delvp22CD-expressing cells, 5-FC had no cytotoxic effects on 9L cultures. At both time-points, expression of even as little as 5% vp22CD or delvp22CD caused a significant decrease in colony Vp22CD fusion enhances bystander effect and therapeutic benefit KC Lee et al formation; however, the cytotoxic effect was more dramatic in vp22CD-expressing cocultures (surviving fraction 0.2 for vp22CD and 0.4 for delvp22CD at 12 h).
More importantly, at all coculture percentages, vp22CD showed a significant (Po0.05) reduction in surviving fraction when compared to delvp22CD at the same percentage. This increased bystander effect was observed despite the fact that these two cell lines were demonstrated to have similar: growth rates, CD expression, CD activity, and sensitivity to both 5-FC and 5-FU ( Figure 1 ).
Tumors expressing vp22CD are more responsive to treatment as compared to delvo22CD-expressing tumors
Given that a difference in bystander effect was demonstrated in an in vitro system, we next wanted to test if this increased effect also was maintained in vivo. Tumor xenografts were established in nude mice that were comprised of either 50 or 20% vp22CD or delvp22CD (with wild-type 9L cells making up the remainder). Once tumors had reached a mean volume of 80-100 ml, tumorbearing animals were treated with 5-FC (500 mg/kg daily for 10 days) or PBS as control ( Figure 3 ). Tumor growth delay with 5-FC treatment was then calculated for each mixed tumor type when compared to the same tumors treated with PBS. Tumors expressing 20% delvp22CD had only a minimal delay in tumor growth following 5-FC treatment as compared to PBS-treated animals, which was not statistically significant (growth delay of 1.3 days, P40.05). In the case of 50% delvp22CD, there was a more robust delay in tumor growth (growth delay of 6.1 days), which was significant compared to PBS-treated control (P ¼ 0.01). However, attesting to an enhanced bystander effect, both the 50 and 20% expressing tumors had enhanced tumor growth delay when expressing vp22CD when compared to Vp22CD fusion enhances bystander effect and therapeutic benefit KC Lee et al delvp22CD (Figure 3a and b). vp22CD tumors, 50%, exhibited a statistically significant increase in growth delay (growth delay of 16.6 days) as compared to the PBS-treated controls (P ¼ 0.01) and its delvp22CD counterpart (P ¼ 0.045). vp22CD tumors, 20%, had an approximate 13-day delay in tumor growth, which was statistically significant compared to PBS-treated controls (Po0.03) and its 20% delvp22CD counterpart (Po0.01). Interestingly, 50 and 20% vp22CD tumors displayed similar growth delay ( Figure 3c and d), and 20% vp22CD expression actually imparted a greater growth delay than even 50% delvp22CD ( Figure 3d ).
F MRS reveals increased in vivo 5-FC conversion in vp22CD-expressing mixed tumors
To explore possible reasons for the increased efficacy of the vp22CD tumor observed by enhanced tumor growth delay, MRS techniques were used to examine potential differences in 5-FC metabolism in vivo. 9L tumors expressing either 50 or 20% vp22CD or delvp22CD were developed subcutaneously in the flanks of nude mice.
When tumors reached approximately 80-100 ml in volume, a single intraperitoneal (i.p.) injection of 5-FC (1000 mg/kg) was given and 19 F MRS was used to detect conversion of 5-FC to 5-FU. The data shown in Figure 4a are summations of 15 spectra acquired over 5 h. In the case of 50 and 20% delvp22CD, a definitive 5-FC peak is shown; however, despite documented growth delay in the 50% delvp22CD tumors (Figure 3a and d) , the amount of 5-FU produced was below the threshold of detection by 19 F MRS. However, in tumors expressing vp22CD, a significant buildup of 5-FU was detected during the 5-h period, with the 50% expressing tumor yielding nearly 50% conversion of injected 5-FC to 5-FU (top, right of Figure 4a ), while a smaller percentage conversion was detectable in the 20% expressing tumor (bottom, right of Figure 4a ). Thus, although vp22 lacks any increased enzymatic function, a significant increase in 5-FU production was observed within mixed tumors expressing vp22CD as compared to delvp22CD-expressing tumors, and the increased growth delay for the 20 and 50% vp22CD-expressing tumors correlated with the increased 5-FU production observed in vivo. Vp22CD fusion enhances bystander effect and therapeutic benefit KC Lee et al
In addition to tumor growth delay and 19 F MRS, tumor sections of the mixed tumors were analyzed by immunohistochemistry to confirm expression of vp22CD and delvp22CD and to evaluate any transport of CD by vp22. Since, upon translocation, vp22-containing proteins have been shown to localize to the nucleus, sections were costained with an anti-CD antibody (to identify vp22CD or delvp22CD expression) and with 4 0 ,6-diamidino-2-phenylindole (DAPI) for nuclear staining ( Figure  4b ). In the tumors expressing 20% delvp22CD, the enzyme was only identified in the cytoplasm of some cells, which indicates expression of the protein, but a lack of nuclear localization of the fusion construct (bottom row of Figure 4b ). However, with tumors expressing 20% vp22CD, not only were a greater portion of the cells shown to contain CD immunoreactivity (top row of Figure 4b ), but these sections also followed known patterns of vp22 distribution where expressing cells exhibited cytoplasmic localization of CD and were flanked by cells exhibiting nuclear localized CD.
Adenovirus-mediated gene therapy is enhanced by vp22, as revealed in tumor growth delay and 19 
F MRS
To evaluate an in vivo model of GDEPT, adenoviral expression vectors were generated for vp22CD (Ad-EF_vp22CD) and wild-type CD (Ad-EF_CD) driven by the Elongation Factor 1 (EF1) promoter. 9L subcutaneous tumors were then established in the flanks of nude mice, and, when tumors had reached a volume of 30-50 ml, virus particles (Ad.Lacz, Ad-EF_vp22CD, or Ad-EF_CD) were injected on days 1 and 3 before treating with 5-FC (500 mg/kg i.p. daily for 10 days starting on day 4) ( Figure 5 ). In tumors expressing CD, a specific growth delay of 4 days was observed as compared to the LacZ control tumors (P ¼ 0.001). Consistent with Figure 4 (a) 19 F MRS was performed on mixed 9L tumors expressing 50% vp22CD (top, right), 20% vp22CD (bottom, right), 50% delvp22CD (top, left), and 20% delvp22CD (bottom, left). Subcutaneous tumors were established (Materials and methods) and spectroscopic measurements (Materials and methods) were initiated when tumors reached approximately 100 mm 3 . Upon administration of 5-FC (1000 mg/kg), spectra were acquired every 20 min for 5 h and the data represent the summation of all 15 20-min acquisitions. vp22CD (50%) (top,right) and vp22CD (20%) (bottom, right) both exhibit the 5-FU peak downfield (À1.1 p.p.m.) from the main 5-FC peak. (b) Subcutaneous 9L mixed tumors expressing 20% vp22CD or delvp22CD were established in the flank of athymic mice. Tumors were grown to approximately 100 mm 3 and then excised for cryosectioning. Immunohistochemical analysis was performed on the cryosections of 20% vp22CD (top panels) and 20% delvp22CD (bottom panels) using anti-CD antisera (left column) for staining cells containing CD, DAPI (middle column) for nuclear staining, and an overlay image was generated (right column).
Vp22CD fusion enhances bystander effect and therapeutic benefit KC Lee et al the stable cell line experiments, expression of transduction with the vp22CD fusion protein followed by 5-FC treatment afforded a doubling of this specific growth delay to 8 days (P ¼ 0.0005 versus LacZ and P ¼ 0.008 versus CD).
Subsequently, 19 F MRS was performed to examine the potential differences in 5-FC metabolism in vivo and determine any correlation between in vivo 5-FU levels and the enhanced specific growth delay that was observed. 9L tumor xenografts at a volume of 30-50 ml were injected with adenoviral particles (LacZ, Ad-EF_CD, or Ad-EF_vp22CD) intratumorally on days 1 and 3. Subsequently, a single i.p. injection of 5-FC (1000 mg/kg) was given on day 4 and 19 F MRS was immediately followed to monitor the presence of 5-FC and 5-FU within the tumors. The data shown in Figure 6a are a summation of 15 spectra acquired over 5 h. As expected, the control LacZ tumor displayed a single 5-FC peak, indicating accumulation of the prodrug at the tumor site during the data collection period and the lack of any detectable 5-FU during the same period. In the case of the CD-transduced tumor, a definitive 5-FC peak was demonstrated; however, despite documented growth delay in these tumors (see Figure 5b) , 5-FU production was below the threshold of detection by 19 F MRS. However, in tumors transduced with vp22CD, a similar accumulation of 5-FC occurred, but this was followed by a significant buildup of 5-FU during the 5 h time course after treatment.
In order to further evaluate this observation, tumors were transduced in the same manner by adenoviral injection of LacZ, CD, or vp22CD viruses, and then were excised and assayed for the level of CD activity without prior 5-FC treatment. Using the same amount of protein extract, the level of CD activity in the LacZ tumor was negligible, while the CD tumor had comparable levels of 5-FC conversion as the vp22CD-transduced tumor (Figure 6b) . Thus, vp22CD did not appear to alter viral transduction or baseline CD activity in cellular extracts, but it did result in a net increase in 5-FU generation within intact tumors. The enhanced production of 5-FU in vp22CD-expressing tumors is also consistent with the enhanced growth delay observed in both stable cell-lines and adenoviral transduced tumors. Vp22CD fusion enhances bystander effect and therapeutic benefit KC Lee et al
Discussion
The original impetus for the GDEPT strategies for cancer therapy was the lack of a therapeutic index for most traditional chemotherapeutics. The indiscriminate killing of cancer cells and normal cells by most chemotherapies leads to limitations on efficacy due to the need to minimize systemic toxicity. 39 However, GDEPT strategies aim to overcome this issue through local production of cytotoxic metabolites at the tumor site, while alleviating the burden on systemic tissues. 40, 41 The most widely used GDEPT strategy to date employs the HSVtk as the suicide gene coupled with the relatively nontoxic GCV as the prodrug. Introduction of this suicide gene into tumor cells leads to sensitivity to GCV, while normal cells not expressing the transgene are unaffected. The HSVtk/ GCV strategy has been shown to exhibit some level of bystander effect, where an expressing cell could activate the prodrug and kill an unexpressing bystander. 42 However, in the case of the HSVtk system, the bystander effect is limited by the charged nature of the phosphorylated metabolites of GCV, which limit their ability to transit across the cellular membrane to adjacent cells. As previously mentioned, the HSVtk system has been demonstrated to depend upon gap junctions for a bystander effect with little transit of phosphorylated GCV in the absence of gap junctions. 4 More recently, the combination of CD/5-FC has been shown to have a more potent bystander effect due to the fact that 5-FC and 5-FU are both membrane permeable, allowing transit to adjacent cells, where 5-FU can be further metabolized to the final cytotoxic moieties. 2, 3 Our previous studies have explored several avenues to maximize the efficacy of this GDEPT strategy, such as utilizing the yeast CD enzyme, which is more catalytically efficient at 5-FC/5-FU conversion as compared to bacterial CD, 5, 6 the extracellular expression of CD to enhance intratumoral generation of 5-FU, 43 or the use of a double-suicide gene which not only converts 5-FC to 5-FU, but can also further metabolize 5-FU to its toxic metabolite FUMP. 8 In the current study, we attempted to improve the CD GDEPT strategy by specifically addressing the bystander effect of the system. Although 5-FU diffuses from cell to cell, the conversion of 5-FC to 5-FU only occurs only within CD-expressing cells, which may limit the bystander effect. Indeed, the CD system has even been utilized as a negative selection system in vitro, so obviously it does not offer a perfect bystander effect. 44 Therefore, a uniform distribution of CD may further aid the bystander effect by providing a diffuse base where conversion occurs, thereby potentially increasing local conversion of 5-FC to 5-FU. To achieve this goal, the HSV tegument protein vp22 was fused to the yeast CD and evaluated using in vitro and in vivo techniques.
From a biochemical perspective, fusion of vp22 to CD did not enhance or ablate the enzymatic action of CD. Vp22CD-expressing cells showed comparable sensitivities to 5-FC as delvp22CD and cells expressing either fusion had similar sensitivities to 5-FU as compared to wild-type 9L. However, clonogenic survival assays using mixed populations of cells clearly demonstrated that the translocatable vp22CD enhanced the cytotoxicity to nonexpressing bystander cells when treated with 5-FC as compared to the nontranslocatable delvp22CD. These data imply that the added property of protein translocation significantly enhances the bystander killing of this GDEPT strategy in vitro and that this effect is directly attributed to trafficking CD to neighboring cells and not due to any change in enzyme activity.
In vitro cell culture experiments performed on cell monolayers allowed for maximal distribution of 5-FU generated from expressing cells by diffusion through the culture medium may have artificially optimized the bystander effect. This, therefore, could have underestimated the effect of the vp22CD system. However, in an in vivo system where 5-FU would need to penetrate several cell layers to potentiate the bystander effect, fusion of vp22 to CD could greatly improve the innate bystander effect of the CD GDEPT strategy. The enhanced spread of CD was evidenced in Figure 4 , in which a qualitative difference between vp22CD and delvp22CD tumors was observed, where nuclear localization was present in vp22CD-expressing tumors and lacking in delvp22CD tumors. This pattern was consistent with previous reports where a functional vp22 led to translocation of the fusion protein to neighboring cells accumulating within the nucleus, whereas the truncated form of vp22 does not allow for either translocation or nuclear localization. Furthermore, the tumors expressing various percentages of vp22CD were more responsive to treatment than delvp22CD tumors at both 50 and 20% expression. Interestingly, tumors expressing 20% vp22CD showed an even greater growth delay than 50% expressing delvp22CD. This, perhaps, suggests that even 20% percent of the cells expressing vp22CD enabled the spread of cytosine deaminase activity to adjacent cells, allowing over 50% of the cells to convert 5-FC to 5-FU. Additionally, 19 F MRS demonstrated a marked increase in 5-FU production with the 20% vp22CD tumor as compared to 50% delvp22CD tumor, which correlated well with the observed results in tumor growth delay. Consistent with this, 19 F MRS also showed more 5-FU production in the 50% vp22CD tumor compared to the 20% vp22CD with tumor growth curves, suggesting a better response, although this did not achieve statistical significance.
Although there may be numerous hypotheses to explain why an increase in 5-FU production within the 50 versus 20% vp22CD tumor did not translate into significant growth delay, one possibility is the protection of the 'factory' cells by the Good Samaritan effect. Previously, using HSVtk/GCV it was observed that in a mixed population of cells there was a significant accumulation of phosphorylated GCV in the factory cell, which lead to their premature death prior to the ability to kill significant numbers of bystander cells. The Good Samaritan effect was observed when gap junctional communication-competent cells were cocultured with the HSVtk-expressing cells, and as a result these were able to decrease the concentration of phosphorylated GCV in the factory cells, allowing them to live longer and convert a greater amount of GCV in the long run. 45 In a similar experiment, we have previously analyzed a soluble-secreted form of bacterial cytosine deaminase, which similarly allowed the factory cells to produce a greater amount of 5-FU in culture before inhibiting thymidylate synthase and causing cell death to the factory cells. 43 Vp22CD may be functioning in a similar fashion, where, although the 50% expressing tumors formed a higher amount of 5-FU at an early time-point, it
Vp22CD fusion enhances bystander effect and therapeutic benefit KC Lee et al is possible that the greater percentage of expressing cells and the higher concentration of 5-FU resulted in early death of the factory cells. While in the 20% expressing tumors, there was likely a greater Good Samaritan effect such that, over the course of a 10-day treatment with 5-FC, there was similar growth delay even though the initial 19 F-MRS had suggested higher production of 5-FU in 50% tumors. Although not directly evaluated within our vp22CD data, it is not entirely unreasonable that the Good Samaritan effect and the bystander effect may operate in conjunction to result in an enhanced therapeutic benefit.
Although mixed tumors demonstrated increased growth delay when expressing a translocating CD, those experiments utilized tumors that were generated with vp22CD-expressing cells spread homogeneously throughout the whole tumor. To more fully evaluate this technique in vivo, transduction of tumors with adenovirus was performed, where we again demonstrated that vp22CD retained its advantage over CD alone. In this adenoviral transduction model, vp22CD had a specific growth delay of just over 7 days versus LacZ (P ¼ 0.005) and 4 days versus CD (P ¼ 0.008). Interestingly, 19 F MRS provided a unique discovery that vp22CD transduced tumors generated greater levels of 5-FU as opposed to CD. Surprisingly, the level of total CD enzyme activity was determined to be comparable between CD and vp22CD transduced tumors using lysates in an in vitro CD activity assay. Based on in vitro studies demonstrating similar enzymatic activity between a translocating and nontranslocating CD, the discrepancy between the 19 F MRS data showing increased 5-FU production with vp22CD, while demonstrating similar levels of CD enzyme activity between both forms of CD, suggests that the property of CD translocation led to greater 5-FC conversion in vivo. The leading hypothesis for this bystander effect can be rationalized through understanding the nature of the microenvironment when adenoviral particles are injected intratumorally. Following administration of the particles, the spread of viral transduction is limited; therefore, only cells located along the needle track become expressers of the chimeric protein, which may lead to compartmentalization of CD activity within limited areas of the tumor and localized 5-FC to 5-FU conversion within these microregions. 46 More specifically, only focal points of cells along the needle track will be transduced with CD and therefore only these will allow the local 5-FC in the microregions to be converted to 5-FU, while other regions of the tumor where 5-FC is present will go unconverted. However, in the case of vp22CD, although only the cells along the needle track will express the chimeric protein, translocation of vp22CD should lead to spread of CD to nonexpressing cells, thus allowing for greater dispersal of CD activity to convert 5-FC not only within transduced cells, but also within untransduced cells beyond the needle track. A greater total portion of the 5-FC contained within the tumor will thus be exposed to the enzyme, allowing conversion to 5-FU. This is a hypothesis that has been postulated previously, but only through the use of noninvasive 19 F MRS were we able to demonstrate this enhanced conversion of 5-FC to 5-FU even when tumor extracts indicated a similar level of CD activity within the tumor.
Although the bystander effect is the likely cause for the observed enhancement in therapeutic efficacy, there may be other avenues implicit in this chimeric translocating vp22CD that leads to enhanced benefit. For example, perhaps the nuclear localization attributed by vp22 localizes CD in proximity with the DNA and RNA synthesis machinery, thereby increasing cytotoxic effect as opposed to cytosolic localization. However, a point against this theory is apparent in the fact that stable cell lines expressing vp22CD or delvp22CD exhibited little difference in 5-FC sensitivity (Figure 1 ) using 100% cultures.
In conclusion, this study provided in vitro validation of vp22CD for enhanced bystander effect, which translated to enhanced therapeutic benefit. Moreover, 19 F MRS provided unique in vivo evidence that protein translocation indeed leads to differences in 5-FC to 5-FU conversion as compared to the nontranslocating CD. In addition to our studies, there have also been many other approaches in overcoming the limitations and improving the therapeutic benefit of this CD GDEPT strategy. As previously mentioned, early works have demonstrated greater efficacy using a yeast CD enzyme as compared to the bacterial homologue. We also have previously reported on an improved GDEPT system using a more catalytically active CD-UPRT bifunctional protein, leading to greater conversion of 5-FC to 5-FU and FUMP. We believe that fusion of these two constructs, a better enzyme in CD-UPRT and increased bystander effect with vp22CD, will provide another added benefit of this GDEPT strategy and take this paradigm of suicide gene therapy one step closer to reality.
Materials and methods

Stable cell lines
Parental 9L cells were cultured in DMEM medium containing 10% heat-inactivated fetal bovine serum, 1% L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin at 371C in an atmosphere of 5% carbon dioxide. The 9L cells were stably transfected with plasmids pEFvp22CD and pEFdelvp22CD. The transfected 9L cell lines (9L/vp22CD and 9L/delvp22CD) were grown in the presence of 0.6 mg/ml of G418. In total, 12-15 clones were isolated and the best-expressing clones were verified by Western blotting. Clones expressing each of the two proteins were selected for further analysis based on similar expression levels (by western analysis) and enzyme activity.
Western analysis
9L/vp22CD and 9L/delvp22CD clones were washed with PBS, lysed with NP-40 buffer containing a protease inhibitor mixture. The lysates were assayed for protein concentrations using the Bio-Rad Dc protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA). After quantitation, an equal volume of Laemmli buffer was added to each sample. The extracts were then boiled for 5 min and 20 mg of protein was loaded and resolved by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis. The resolved samples were transferred onto a nitrocellulose membrane (Gelman Sciences, Ann Arbor, MI, USA) for Western blot analysis using a rabbit polyclonal anti-yCD 5 at a 1:20 Â 10 3 dilution, followed by a goat anti-rabbit antibody conjugated to horseradish Vp22CD fusion enhances bystander effect and therapeutic benefit KC Lee et al peroxidase and visualized using enhanced chemi-luminescence (Pierce, Rockford, IL, USA).
CD enzyme assay
CD enzyme activity was quantified as described previously. 6, 8 The assay was performed in a 30-ml reaction volume to which 0.5-8 mg of protein extract was incubated with 100 mM 5-FC and 0.5 mM 5-(6- 
Clonogenic assay
To determine the cytotoxic effect of 5-FC on bystander cells, cocultures of 5, 10, 20, or 50% 9L/vp22CD cells or 9L/delvp22CD cells with 95, 90, 80, or 50% 9L cells were plated in DMEM medium containing 10% heat-inactivated fetal bovine serum, 1% L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin at 371C in an atmosphere of 5% carbon dioxide for 36 h, at which time the medium was changed to one supplemented with PBS or 100 mM 5-FC. Cells were treated with the drug for 12 or 20 h, at which point they were plated for colony formation, and after 7-10 days the dishes were fixed and stained with crystal violet before counting. 47 The data presented are the mean and standard error from at least three experiments.
Immunohistochemistry
Sections (5 mm thick) of frozen tumor tissues were cut and mounted on slides. Tissues were fixed in 4% paraformaldehyde for 15 min at room temperature and then in 100% ice-cold methanol for 5 min. Subsequently, the slides were rinsed thoroughly with 1 Â PBS with 0.1% Tween 20 and nonspecific binding sites were blocked with 10% normal donkey serum in PBS for 1 h at room temperature. Anti-CD antibody was diluted 1:300, in PBS containing 1% donkey serum, 0.05% Tween 20 and incubated with sections overnight at 41C. After being washed in PBS (thrice for 10 min), sections were incubated with a 1:400 goat anti-rabbit Cy3 for 30 min at room temperature. After three further PBS washes, sections were counterstained with 1 mg/ml DAPI for 1-2 min at room temperature and mounted in aqueous mounting solution. The slides were air-dried overnight and observed under the fluorescent microscope ( Â 100).
In vivo mixed tumor studies
Subcutaneous mixed 9L tumors were induced in the flanks of 6-week-old male nu/nu CD-1 athymic mice (Charles Rivers Laboratories) by implantation of cell suspensions (5 Â 10 5 cells) consisting of 50 or 20% stable vp22CD or delvp22CD cells, with the remainder being wild-type 9L cells. Parental 9L cells and 9L's stably expressing vp22CD or delvp22CD growing in log phase were trypsinized and counted by Coulter counter. Trypan Blue viability assays were performed to normalize for viable cells of each cell type. Tumors were measured using caliper measurements in two dimensions. Tumor volumes were then calculated using the formula: p/6 (length Â width) 2 ). When tumors reached approximate volumes of 80-100 ml as calculated using a previously reported method, treatment was initiated by i.p. injection of 5-FC (500 mg/kg in saline) or saline (untreated controls) administered daily for 10 days. The data are presented using relative tumor volumes (factor of initial volume) versus time, and untreated controls (n ¼ 4) are designated as 50:50 vp22CD, 50:50 delvp22CD, 20:80 vp22CD, and 20:80 delvp22CD, with treated groups (n ¼ 5) designated with '+'.
In vivo adenovirus studies 9L tumors were established by injecting 5 Â 10 5 cells, counted using a Coulter counter, subcutaneously in the flanks of 6-week-old male nu/nu CD-1 immunodeficient mice (Charles Rivers Laboratories). Tumor volumes were determined using caliper measurements as described previously. At day 10 (tumors at B50 mm 3 ) and 12, adenovirus (at a dose of 1 Â 10 10 particles) encoding LacZ (n ¼ 4), CD (n ¼ 5), or vp22CD (n ¼ 5) was injected intratumorally using a four-poke method. On day 13, animals with tumors approximately 100-150 mm 3 in volume were given daily i.p. injections of 5-FC (500 mg/kg) for 10 days. The data are presented using relative tumor volumes (factor of initial volume) versus time.
Tumor growth delay
Tumor volumes were obtained using caliper measurements and the previously stated equation and volumes were collected every 2 days until cessation of the experiment. Growth curves were plotted and the mean time for the control group tumors to reach five times the initial volume was determined. Subsequently, the mean time for tumors from each experimental group to reach five times the initial pretreatment volume was also determined and subtracted by the mean time of the control group to obtain the tumor growth delay value. Tumor growth delay represents the difference in days for treated groups to reach five times the initial volume as compared to the control group.
F magnetic resonance spectroscopy
Animals with established tumors, as previously described, were anesthetized with isofluorane, given an i.p. dose of 1 g/kg 5-FC, and restrained on a specially constructed plastic jig that immobilizes the tumorbearing hind limb. The conscious mouse was then positioned so that the tumor was directly under the surface coil and placed at the isocenter of the magnet. This procedure, including optimizing the magnetic field homogeneity to a typical proton line width of 60 Hz and tuning the coil to the fluorine frequency, required approximately 20 min. Spectra were then acquired sequentially every 20 min for a minimum of 3 h. 19 F-MR spectra were obtained at 282.3 MHz by using a Vp22CD fusion enhances bystander effect and therapeutic benefit KC Lee et al Varian Unity Inova system equipped with a 7-T, 18.3-cm horizontal bore magnet. A custom-built, 6-mm diameter, single-turn circular surface coil tunable to both the proton (300.7 MHz) and fluorine frequencies was used as a transmitter and receiver. Spectra were acquired as the average of 256 transients (free induction decays) collected in 8192 data points by using a 6-ms pulse width (corresponding to a 901 flip angle at a depth of 2.7 mm), 4.65-ms repetition time, and a 20-kHz spectral width. A 200-ml microfuge tube containing NaF in normal saline was placed just above the surface coil to provide an external chemical shift and concentration standard. The transmitter frequency was offset to place the center of the spectrum midway between the NaF and 5-FC resonance frequencies. Each spectrum was apodized with a 60-Hz exponential line-broadening function before Fourier transformation, individually phased, and baseline corrected with a cubic spline method using the VNMR software (Varian, Inc.).
